1,183
Participants
Start Date
November 7, 2016
Primary Completion Date
July 19, 2018
Study Completion Date
July 19, 2018
MenACYW conjugate vaccine
Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine; 0.5 milliliter (mL), Intramuscular
MMR
Measles, Mumps, and Rubella Virus Vaccine Live; 0.5 mL, Subcutaneous
Varicella
Varicella Virus Vaccine Live; 0.5 mL, Subcutaneous
DTaP-IPV-HB-Hib
Diphtheria, Tetanus, Pertussis (acellular component), Hepatitis B, Poliomyelitis (inactivated), and Haemophilus influenzae type-b conjugate vaccine (adsorbed); 0.5 mL, Intramuscular
PCV13
Pneumococcal 13-valent Conjugate Vaccine; 0.5 mL, Intramuscular
Wŏnju
Pathum Wan
Rajthevi
Ilsan
Acapulco
Daegu
Gwangju
Tlaltizapán
Jeju City
Moscow
Murmansk
Saint Petersburg
Saint Petersburg
Saint Petersburg
Smolensk
Krasnodar
Kazan'
Samara
Perm
Yekaterinburg
Novosibirsk
Tomsk
Barnaul
Mexico City
Ansan
Anyang
Daejeon
Incheon
Seoul
Seoul
Seoul
Seoul
Seoul
Seoul
Seoul
Suwon
Yangsan
Sanofi Pasteur, a Sanofi Company
INDUSTRY